Sonoma Pharmaceuticals reports higher revenue

BOULDER — Sonoma Pharmaceuticals Inc. (Nasdaq: SNOA) reported record revenue and a lower net loss for the second quarter of its fiscal year.

The Boulder-based company, which develops wound-care and dermatology products, recorded revenue of $5.6 million for the quarter ended Sept. 30, up 57% from $2 million in the same period a year ago.

Sonoma’s Q2 loss of $500,000 represented a 12% improvement compared with a loss of $600,000 a year ago.

The company’s patented Microcyn technology is based on stabilized hypochlorous acid, or HOCl, and is used for wound care, dermatological conditions, podiatry, nasal care, animal health care, and eye, oral and nasal care.

“We are thrilled to report the highest quarterly revenues in Sonoma’s history,” Amy Trombly, CEO of Sonoma Pharmaceuticals, said in a statement. “This achievement reflects the exceptional work of our team in expanding our distribution network, launching new products, and obtaining key regulatory clearances. While we anticipate some quarterly fluctuations as we continue to grow, we expect Sonoma’s overall trajectory to be strongly positive, with increasing adoption of our high-quality products by both consumers and healthcare providers and solidification of our position as the global leader in the HOCl industry.”

Sonoma in August launched the sale of diaper-rash products into Walmart and other U.S. retailers and in October released a wound-cleanser product, to be distributed into hospital systems, home health care and other medical settings.

Sonoma’s stock closed unchanged Wednesday at $3.76.

Share on Facebook on LinkedIn